4-substituent-2-hydroxylmorpholine-3-one and preparation method thereof

A molecule with neural activities, especially 4-substituent-2-hydroxymorpholin-3-one, as a new intermediate of neurokinin-1 receptor antagonist aprepitant, and preparation method thereof.

Method for preparing linezolid intermediate

Disclosed is a new method for preparing a methyl substitute of a linezolid intermediate, (S)-2-(3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazoline) (I), wherein the intermediate (I) is obtained by the cyclization of 3-fluoro-4-morpholinophenyl isocyanate (II) and epoxy compound (III). This process has a short process route, low cost, easy operation, and high yield, so is suitable for a large-scale industrial production.

Novel synthesis process of antiparasitic drug, namely selamectin

The invention provides a novel selamectin key intermediate and a preparation method thereof, and further provides a novel synthesis process of selamectin. The process comprises the steps of: by taking doramectin as the starting raw material and then obtaining selamectin through hydrogenation, oxidizing reaction, oximation and desugaring. The novel process disclosed by the invention has the advantages of being few in step, simple for operation, high in yield and low in cost and pollution and is more applied to large-scale industrial production.

New crystal form of ixabepilone, and preparation method thereof

The invention provides a new crystal form of ixabepilone. The new crystal form can be characterized by X-ray powder diffraction (XRD) spectra, differential scanning calorimetry (DSC) spectra and infrared absorption spectra. Meanwhile, the invention also provides a method for preparing the new crystal form of ixabepilone.

Preparation method of linezolid intermediate

A new preparation method of a linezolid intermediate (S)-2-((3-(3-fluoro-4-morpholinephenyl)-2-oxo-5-oxazoline)methyl substituent (I) is characterized in that the intermediate (I) is obtained through cyclizing 3-fluoro-morpholinephenyl isocyanate (II) and an epoxy compound (III). The method has the advantages of short process route, low cost, simple operation, high yield, and suitableness for the industrialized production.

Differnet-end double-display type earth resistance tester

The invention provides a different-end double-display type earth resistance tester and relates to the technical field of lightning protection detection earth resistance testing. An earth resistance testing unit is connected with a communication unit in a wired mode, and the communication unit comprises a data transmitter, a data receiver and a display; the earth resistance testing unit converts direct current signals into alternating current signals through a frequency generator for testing, current and voltage signals of an auxiliary testing electrode are collected under the control of a single chip microcomputer, the signals are subjected to ADC (analog to digital converter) sampling after the amplification and the filtering, converted digital signals are transmitted to a microprocessor in the single chip microcomputer for computational processing, and the tested earth resistance value is obtained and is displayed through the display of the tester. The different-end double-display type ...

Illegal invasion detection system and illegal invasion detection method

The invention discloses an illegal invasion detection system and an illegal invasion detection method. The system comprises a central processing unit module and an alarm device. The input end of the central processing unit is connected with a first laser receiver and a second laser receiver, the output end of the central processing unit module is connected with a first laser transmitter and a second laser transmitter, the first laser receiver and the first laser transmitter both are arranged in a first region, and the second laser receiver and the second laser transmitter both are arranged in a second region. The method comprises the following steps of: 1, setting time intervals T1 and T2; 2, after each time interval T1, encrypting a laser transmitting direction; 3, after each time interval T2, encrypting a laser transmitting position; 4, judging whether illegal invasion happens, if so, controlling the alarm device to send an alarm signal by virtue of a central processing unit. The system ...

4-substitute-2-hydroxy morpholine-3-one and preparation method thereof

The invention provides molecules with neuro activity action, particularly to a new intermediate 4-substitute-2-hydroxy morpholine-3-one (I) of neurokinin-1 receptor antagonist Aprepitant and a preparation method of the new intermediate.

CRYSTAL FORM OF DABIGATRAN ETEXILATE MESYLATE AND PREPARATION METHOD AND USE THEREOF

The present invention relates to novel crystal forms M and N of dabigatran etexilate mesylate and preparation method and uses thereof, wherein the X-Ray powder diffractogram of the crystal form M has characteristic peaks at the following 2θ diffraction angles: 5.7±0.2°, 6.2±0.2°, 11.2±0.2°, 12.4±0.2°, 18.2±0.2°, 21.4±0.2°, 21.8±0.2° and 23.6±0.2°; and the X-Ray powder diffractogram of the crystal form N has characteristic peaks at the following 20 diffraction angles: 6.0±0.2°, 11.8±0.2°, 18.2±0.2°, 21.6±0.2°, 24.4±0.2°, 27.7±0.2° and 29.7±0.2°. The crystal forms of the present invention have excellent properties in the aspects of leaching time, biological release, chemical stability and processing adaptability. 1. A crystal form M of the dabigatran etexilate mesylate , characterized in that the X-Ray powder diffractogram thereof has characteristic peaks at the following 2θ diffraction angles: 5.7±0.2° , 6.2±0.2° , 11.2±0.2° , 12.4±0.2° , 18.2±0.2° , 21.4±0.2° , 21.8±0.2° and 23.6±0.2°.2. The crystal form M of the dabigatran etexilate mesylate according to claim 1 , characterized in that the X-Ray powder diffractogram thereof also has characteristic peaks at the following 2θ diffraction angles: 16.3±0.2° claim 1 , 22.8±0.2° claim 1 , 25.0±0.2° and 27.3±0.2°.3. The crystal form M of the dabigatran etexilate mesylate according to claim 2 , characterized in that the X-Ray powder XRD diffractogram thereof also has characteristic peaks at the following 2θ diffraction angles : 8.1±0.2° claim 2 , 13.0±0.2° claim 2 , 17.1±0.2° claim 2 , 29.0±0.2°.6. (canceled)7. The method for preparing the crystal form M of the dabigatran etexilate mesylate according to claim 5 , wherein the alcohol is C1-C4 alcohol claim 5 , preferably methanol claim 5 , ethanol claim 5 , isopropanol or n-butyl alcohol; the ketone is C3-05 ketone claim 5 , preferably acetone claim 5 , butanone or pentanone; the ester is C3-C6 ester claim 5 , preferably methyl acetate claim 5 , ethyl acetate or butyl ...

METHOD FOR PREPARING LINEZOLID INTERMEDIATE

Disclosed is a new method for preparing a methyl substitute of a linezolid intermediate, (S)-2-(3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazoline) (I), wherein the intermediate (I) is obtained by the cyclization of 3-fluoro-4-morpholinophenyl isocyanate (II) and epoxy compound (III). This process has a short process route, low cost, easy operation, and high yield, so is suitable for a large-scale industrial production. 4. The process according to claim 1 , wherein the cyclization reaction is performed in the presence of a catalyst claim 1 , preferably claim 1 , the catalyst is a Lewis acid or a mixture thereof.5. The process according to claim 4 , the catalyst is selected from lithium bromide claim 4 , magnesium bromide claim 4 , lithium chloride claim 4 , magnesium chloride claim 4 , magnesium iodide claim 4 , lithium iodide claim 4 , lithium chloride claim 4 , zinc chloride claim 4 , tetra-n-butylammonium bromide claim 4 , tetra-n-butylammonium chloride claim 4 , or any mixture thereof.6. The process according to claim 4 , the catalyst is selected from lithium bromide claim 4 , magnesium bromide claim 4 , magnesium iodide claim 4 , or any mixture thereof.7. The process according to claim 1 , wherein the cyclization reaction is performed in a solvent claim 1 , preferably claim 1 , the solvent is an aprotic solvent or a mixture thereof.8. The process according to claim 7 , the aprotic solvent includes but not limited to petroleum ether claim 7 , ethyl acetate claim 7 , isoamyl acetate claim 7 , butyl acetate claim 7 , toluene claim 7 , xylene claim 7 , chlorobenzene claim 7 , tetrahydrofuran claim 7 , dichloromethane claim 7 , N claim 7 ,N-dimethylformamide claim 7 , C-Calkanes claim 7 , acetone claim 7 , 1 claim 7 ,4-dioxane claim 7 , acetonitrile claim 7 , or any mixture thereof.9. The process according to claim 1 , wherein the temperature of the cyclization reaction is in the range of 60° C.-150° C.10. The process according to claim 9 , wherein the temperature of ...

Methods of Isolating Naive Regulatory T Cells

This invention relates to the production of isolated naive regulatory T cells by detecting the presence or absence of a panel of surface markers comprising CD3, CD4, CD25, CD45RA, CCR4 and CCR7 on the surface of cells in a population of peripheral blood mononuclear cells (PBMCs); and separating cells on which the presence of the surface markers CD3, CD4, CD25, CD45RA, and CCR7 and the absence of the surface marker CCR4 is detected. Isolated populations of naive regulatory T cells and methods and kits for their production are provided.

4-SUBSTITUENT-2-HYDROXYLMORPHOLINE-3-ONE AND PREPARATION METHOD THEREOF

A molecule with neural activities, especially 4-substituent-2-hydroxymorpholin-3-one, as a new intermediate of neurokinin-1 receptor antagonist aprepitant, and preparation method thereof. 6. The method according to claim 5 , which is characterized in that the solvent used in the reaction is selected from the group consisting of: ethyl acetate claim 5 , C-Calkane claim 5 , benzene claim 5 , toluene claim 5 , paraxylene claim 5 , chlorobenzene claim 5 , orthodichlorobenzene claim 5 , acetone claim 5 , dichloromethane claim 5 , chloroform claim 5 , nitromethane claim 5 , N claim 5 ,N-dimethyl formamide claim 5 , dimethyl sulfoxide claim 5 , 2-butanone claim 5 , C-Calcohols claim 5 , 1 claim 5 ,3-dioxane claim 5 , 1 claim 5 ,4-dioxane claim 5 , tetrahydrofuran claim 5 , acetonitrile claim 5 , 1 claim 5 ,2-dimethyl ethyl claim 5 , water and the mixture thereof; and preferably claim 5 , the solvent is selected from the solvent miscible with water claim 5 , including N claim 5 ,N-dimethyl formamide claim 5 , dimethyl sulfoxide claim 5 , 2-butanone claim 5 , C-Calcohols claim 5 , 1 claim 5 ,3-dioxane claim 5 , 1 claim 5 ,4-dioxane claim 5 , tetrahydrofuran claim 5 , acetonitrile claim 5 , 1 claim 5 ,2-dimethyl ethyl and a mixture thereof; and more preferably claim 5 , the solvent is selected from tetrahydrofuran claim 5 , acetonitrile and the mixture thereof; and most preferably claim 5 , the solvent is tetrahydrofuran.7. The method according to claim 5 , which is characterized in that the reaction temperature for the method is from 30 to 100° C.; and preferably claim 5 , is from 60 to 70° C.8. The method according to claim 5 , which is characterized in that the aqueous glyoxalic acid solution used in the method is selected from an aqueous solution of glyoxalic acid monohydrate claim 5 , and an aqueous glyoxalic acid solution with a mass ratio of 1-99%; and preferably claim 5 , the mass ratio of the aqueous glyoxalic acid solution is 50%.9. Use of the compound according to ...

Mobile phone holding heating device

The invention discloses a heating device for holding and holding a mobile phone, which includes a warming block. The warming block is provided with a working cavity and a mobile phone cavity. The working cavity is provided with a temperature measuring mechanism. The water storage frame on the lower end wall of the working chamber is provided with a clamping mechanism on the upper side of the temperature measuring mechanism, the clamping mechanism includes a clamping block, and two clamping grooves are symmetrically provided on the rear wall of the working chamber. A moving mechanism is provided on the right side of the clamping mechanism, and the moving mechanism includes a contact shaft that is rotatably disposed on the rear wall of the working cavity. The device is easy to operate. After the mobile phone is clamped with two clamping blocks, the heating block is heated. It can heat the water in the water storage cavity. After heating to the moving temperature, it can stop heating excitedly to prevent the heating temperature from being too high and cause users to burn. When the heating is completed, the cleaning block will wipe the screen surface of the mobile phone in order. So that users do not have to manually wipe the screen of the phone.

CRYSTAL FORMS OF BEDAQUILINE FUMARATE AND PREPARATION METHODS THEREFOR

Provided are crystal forms I, II, and III of bedaquiline fumarate, and preparation methods thereof. The crystal forms have high purity, excellent physicochemical properties, and good stability. The preparation methods can effectively improve the quality of products, and are applicable to preparation and mass production of medicines. 1. A crystal form I of (1R ,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-dimethylamino-1-phenyl-2-(1-naphthyl)-2-butanol fumarate , wherein the X-ray powder diffraction pattern thereof has characteristic peaks at 2θ (°) values of 5.6±0.2 , 11.2±0.2 , 22.6±0.2 , 23.1±0.2 , 23.6±0.2 , 29.0±0.2.2. The crystal form I according to claim 1 , wherein the X-ray powder diffraction pattern thereof has characteristic peaks at 2θ (°) values of 3.8±0.2 claim 1 , 16.9±0.2 claim 1 , 18.8±0.2 claim 1 , 19.3±0.2 claim 1 , 20.6±0.2 claim 1 , 20.9±0.2 claim 1 , 21.9±0.2 claim 1 , 26.7±0.2 claim 1 , 28.3±0.2.3. A preparation method of crystal form I of (1R claim 1 ,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-dimethylamino-1-phenyl-2-(1-naphthyl)-2-butanol fumarate claim 1 , wherein the method comprises the following sequence of steps:(1)(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-dimethylamino-1-phenyl-2-(1-naphthyl)-2-butanol fumarate is dissolved in a mixed solvent of methanol and water;(2) the temperature is increased to 50-60° C. and the solution is stirred continuously until the solute dissolved;(3) filtered, the filtrate is stirred to decrease the temperature to 10-25° C.; and(4) crystallized at 10-25° C., filtered to obtain the crystal form I of (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-dimethylamino-1-phenyl-2-(1-naphthyl)-2-butanol fumarate.4. The preparation method according to claim 3 , wherein the weight-to-volume ratio of (1R claim 3 ,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-dimethylamino-1-phenyl-2-(1-naphthyl)-2-butanol fumarate to the mixed solvent of methanol and water is 1:10-50 g/ml claim 3 , preferably 1:10-20 g/ml;the volume percentage of ...

METHOD FOR PREPARING FULLY PROTECTION HEPARIN PENTASACCHARIDE AND INTERMEDIATE THEREOF

Disclosed is a process for chemically synthesizing a pharmaceutical intermediate, in particular to a novel intermediate and novel process for synthesizing an anticoagulant drug fondaparinux sodium intermediate—full protection heparin pentasaccharide. The process has a high reaction efficiency and a simple reaction operation, and enables the reaction intermediate to be easily purified, thus being suitable for the industrialized production of the full protection heparin pentasaccharide. 5. The method according to claim 4 , which is characterized in that: the base is selected from an organic base or an inorganic base claim 4 , wherein the organic base is selected from pyridine or triethylamine claim 4 , and the inorganic base is selected from potassium carbonate claim 4 , sodium carbonate or sodium bicarbonate claim 4 , the acetylation reagent is selected from acetic anhydride or acetyl chloride.8. The method according to claim 7 , which is characterized in that the methylation reagent is selected from diazomethane claim 7 , (trimethylsilyl)diazomethane claim 7 , iodomethane claim 7 , bromomethane or chloromethane.10. The method according to claim 9 , which is characterized in that the oxidizing agent is selected from iodobenzene diacetate claim 9 , calcium hypochlorite or sodium hypochlorite claim 9 , and the catalyst is 2 claim 9 ,2 claim 9 ,6 claim 9 ,6-tetramethyl-1-piperidinyloxy.12. The method according to claim 11 , which is characterized in that the deacetylation reagent is selected from a solution of hydrogen chloride in methanol claim 11 , a solution of hydrogen chloride in ethanol claim 11 , a solution of triethylamine in methanol claim 11 , a solution of triethylamine in ethanol claim 11 , sodium methoxide or sodium ethoxide.15. The method according to claim 14 , which is characterized in that: the base is selected from an organic base or an inorganic base claim 14 , wherein the organic base is selected from pyridine or triethylamine claim 14 , and the ...

4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF

Provided are derivatives substituted by urea associated with 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine-2-amino of formula (I), wherein these compounds may selectively regulate or inhibit an information transmission process controlled by natural or variant tyrosine kinase. Also provided are preparation methods and uses of the compounds. 2. (canceled)3. (canceled)4. (canceled)5. The compound according to claim 1 , wherein A is selected from phenyl claim 1 , naphthyl claim 1 , pyrazolyl claim 1 , and preferably A is phenyl.6. (canceled)7. (canceled)8. The compound according to claim 1 , wherein Ris selected from C1-C10 alkyl unsubstituted or substituted by R claim 1 , 2-10 membered heteroalkyl unsubstituted or substituted by R claim 1 , C3-C8 cycloalkyl unsubstituted or substituted by R claim 1 , 3-8 membered heterocycloalkyl unsubstituted or substituted by R; preferably claim 1 , Ris selected from C1-C5 alkyl unsubstituted or substituted by R claim 1 , 2-5 membered heteroalkyl unsubstituted or substituted by R claim 1 , C3-C6 cycloalkyl unsubstituted or substituted by R claim 1 , 5- or 6-membered heterocycloalkyl unsubstituted or substituted by R; more preferably claim 1 , Ris selected from unsubstituted C1-C5 alkyl claim 1 , unsubstituted C3-C6 cycloalkyl claim 1 , 5- or 6-membered heterocycloalkyl unsubstituted or substituted by R: further preferably claim 1 , Ris selected from unsubstituted C1-C5 alkyl claim 1 , unsubstituted thienyl claim 1 , C1-C4 substituted thienyl; and most preferably Ris methyl.9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. The compound according to claim 1 , wherein Ris selected from fluoro claim 1 , chloro claim 1 , bromo claim 1 , methyl claim 1 , ethyl claim 1 , trifluoromethyl claim 1 , trifluoroethyl claim 1 , trifluoropropyl claim 1 , and preferably Ris fluoro claim 1 , chloro claim 1 , trifluoromethyl claim 1 , methyl.16. The compound according to claim 1 , wherein Ris ...

New synthesis process of antiparasitic drug selamectin

Provided in the present invention are novel key intermediates of selamectin and the preparation method thereof. Also provided is a new synthesis process, using doramectin as a starting material, and obtaining selamectin via hydrogenation, oxidation, oximation and desugaring. The new process of the present invention has few steps, and is simple to operate, high in yield, low in cost and causes little pollution, and is more suitable for large scale industrial production.

Preparation method of 4-(4-amino-3-fluorophenoxy)-n-methylpyridine-2-formamide

The present invention relates to a preparation method of 4-(4-amino-3-fluorophenoxy)-N-methylpyridine-2-formamide capable of enabling 4-chlorine-N-methylpyridine-2-formamide to react with 4-amino-3-fluorophenol in the presence of an inorganic base. The present invention employs the inorganic base to replace potassium t-butoxide in the prior art, thus effectively solving the problem of a potential safety hazard of the potassium t-butoxide in industrial production. In addition, after the reaction is completed, the present invention employs a crystallization method for separation to obtain a reaction product; thus compared with the methods of extraction, concentration and column isolation and purification employed in the prior art, the present invention has a simpler operation and a lower cost, results in less environment pollution and a higher yield, and is very suitable for industrial production.

METHOD FOR PREPARING SOFOSBUVIR CRYSTAL FORM-6

The present invention relates to a method for preparing Sofosbuvir crystal form-6. The method is simple in operation, stable in process condition, good in reproducibility, high in yield rate and high in purity, viscous gel-type products are not formed during the process, the problem of blocking of a discharge port is solved, and the method is suitable for mass industrial production and has high economic value. 1. A method for preparing Sofosbuvir crystalline form-6 , comprising:(a) dissolving Sofosbuvir in an organic solvent to obtain a solution of Sofosbuvir;(b) adding the solution obtained in step (a) to pure water preheated to a certain temperature;(c) cooling the mixed solution obtained in step (b) to −15 to 25° C., preferably 0 to 10° C., to obtain a Sofosbuvir crystal form-6.2. The method according to claim 1 , wherein further comprising the step of incubating claim 1 , stirring and crystallizing the mixed solution obtained in step (b) before step (c).3. The method according to claim 1 , wherein the organic solvent in step (a) is selected from the group consisting of methanol claim 1 , ethanol claim 1 , isopropanol claim 1 , acetonitrile claim 1 , acetone claim 1 , tetrahydrofuran claim 1 , 1 claim 1 ,4-dioxane claim 1 , N claim 1 ,N-dimethylformamide claim 1 , dimethylsulfoxide and mixtures thereof claim 1 , preferably selected from the group consisting of methanol claim 1 , ethanol claim 1 , acetone and mixtures thereof.4. The method according to claim 1 , wherein the volume/mass ratio (ml/g) of the organic solvent to the Sofosbuvir in step (a) is 1:1 to 10:1 claim 1 , preferably 2:1 to 4:1.5. The method according to claim 1 , wherein the preheated temperature of the pure water in step (b) is 30 to 80° C. claim 1 , preferably 40 to 60° C.6. The method according to claim 1 , wherein the volume ratio of the pure water to the organic solvent is 3:1 to 100:1 claim 1 , preferably 4:1 to 20:1.7. The method according to claim 1 , wherein further comprising the step ...

New synthesis process of antiparasitic drug selamectin

Crystalline forms of bedaquiline fumarate and preparation methods therefor

New synthesis process of antiparasitic drug selamectin

4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof

Provided are derivatives substituted by urea associated with 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine-2-amino of formula (I), wherein these compounds may selectively regulate or inhibit an information transmission process controlled by natural or variant tyrosine kinase. Also provided are preparation methods and uses of the compounds.

Method for preparing Sofosbuvir crystal form-6

The present invention relates to a method for preparing Sofosbuvir crystal form-6. The method is simple in operation, stable in process condition, good in reproducibility, high in yield rate and high in purity, viscous gel-type products are not formed during the process, the problem of blocking of a discharge port is solved, and the method is suitable for mass industrial production and has high economic values.

Method for preparing fully protection heparin pentasaccharide and intermediate thereof

Methods of isolating naïve regulatory t cells

This invention relates to the production of isolated naive regulatory T cells by detecting the presence or absence of a panel of surface markers comprising CD3, CD4, CD25, CD45RA, CCR4 and CCR7 on the surface of cells in a population of peripheral blood mononuclear cells (PBMCs); and separating cells on which the presence of the surface markers CD3, CD4, CD25, CD45RA, and CCR7 and the absence of the surface marker CCR4 is detected. Isolated populations of naive regulatory T cells and methods and kits for their production are provided.

Apparatus and method for guiding an instrument

[UNK]

Disclosed is a process for chemically synthesizing a pharmaceutical intermediate in particular to a novel intermediate and novel process for synthesizing an anticoagulant drug fondaparinux sodium intermediate full protection heparin pentasaccharide. The process has a high reaction efficiency and a simple reaction operation and enables the reaction intermediate to be easily purified thus being suitable for the industrialized production of the full protection heparin pentasaccharide.

A Tea Drink with Anti-Alcohol and Liver-Protecting Effects and Preparation Method Thereof

The invention discloses a tea drink with anti-alcohol and liver-protecting effects, which belongs to the technical field of health care products, and comprises the following raw materials in parts by weight: 3-4 parts of Hovenia dulcis, 1-2 parts of Pueraria lobata, 1-2 parts of mulberries (Fructus Mori), 1-2 parts of chrysanthemum (chrysanthemum morifolium), 1-2 parts of Pericarpium citri reticulatae and 1-3 parts of Pu-er ripe tea. The preparation method comprises the following steps: weighing the raw materials; mixing Hovenia dulcis, Pueraria lobata, mulberries, chrysanthemum, Pericarpium citri reticulatae, and Pu-er ripe tea, placing in an extraction tank, adding hot water for extraction, and then adding mulberries for continuous extraction to obtain a mixture; Centrifuging the mixture, collecting supernatant, concentrating, and drying to obtain tea.

Apparatus and method for guiding an instrument

An instrument holder and a method for aligning an instrument for accessing a target within a subject, comprising a first layer, a second layer, an instrument guide with an entry and an exit point, connecting between the two layers and configured to guide the instrument from the entry point to the exit point, wherein the instrument holder is transparent to an imaging system except that the first layer and second layer include markings that are visible by the imaging system.

A medical device for aligning an instrument

The present disclosure generally relates to an apparatus and a method for aligning an instrument, such as a needle, relative to a plane for insertion into the body of a subject. The present disclosure provides a medical device having a needle holding device and an adjustment mechanism for allowing a main body of the medical device to be aligned to the plane. The medical device comprises a main body, an adjustment mechanism and a guide limiter. Said adjustment mechanism comprises a knob; a screw connected to the knob; a receiver for receiving the screw, the receiver having a pivot at its bottom section; and a vertical gap formed between said receiver and a lateral extension of a main body of the medical device.

Methods of isolating naïve regulatory t cells

This invention relates to the production of isolated naive regulatory T cells by detecting the presence or absence of a panel of surface markers comprising CD3, CD4, CD25, CD45RA, CCR4 and CCR7 on the surface of cells in a population of peripheral blood mononuclear cells (PBMCs); and separating cells on which the presence of the surface markers CD3, CD4, CD25, CD45RA, and CCR7 and the absence of the surface marker CCR4 is detected. Isolated populations of naive regulatory T cells and methods and kits for their production are provided.

Apparatus and method for guiding an instrument

An instrument holder and a method for aligning an instrument for accessing a target within a subject are disclosed, wherein the instrument holder comprises a first layer, a second layer, an instrument guide with an entry and an exit point that connects between the two layers and also guide the instrument from the entry point to the exit point, and wherein the first layer and second layer include markings that are visible by the imaging system and form a predefined pattern when the first layer and second layer are aligned. In another embodiment, the instrument guide is located within the second layer and the first layer include markings that are visible by the imaging system and also form a predefined pattern with the instrument visible by the imaging system when the first layer and second layer are aligned. Preferably, the markings are radio-opaque and/or are in form of lines, linear graduations, arrows or arrow heads or cross-hairs.

Wire drawing device for metal mobile phone back case

The invention discloses a wire drawing device for a rear case of a metal mobile phone, which includes a fuselage, and all of the support rods are symmetrically mounted on both sides of the fixing block. The fixing block is provided with a first spring space and the motor base moves to a third position The left side of the space is stuck and positioned. The left and right movement of the frosted stone is controlled by the threaded screw. The frosted stone contacts the mobile phone case to move left and right. Good control of cleaning time and cutting time of plastic film, the call spring controls the pressure block to slide up and down flexibly, which can make the plastic film fit without damaging the surface of the drawn mobile phone case.

Crystal form of dabigatran etexilate mesylate and preparation method and use thereof

The present invention relates to novel crystal forms M and N of dabigatran etexilate mesylate and preparation method and uses thereof, wherein the X-Ray powder diffractogram of the crystal form M has characteristic peaks at the following 2θ diffraction angles: 5.7±0.2°, 6.2±0.2°, 11.2±0.2°, 12.4±0.2°, 18.2±0.2°, 21.4±0.2°, 21.8±0.2° and 23.6±0.2°; and the X-Ray powder diffractogram of the crystal form N has characteristic peaks at the following 2θ diffraction angles: 6.0±0.2°, 11.8±0.2°, 18.2±0.2°, 21.6±0.2°, 24.4±0.2°, 27.7±0.2° and 29.7±0.2°. The crystal forms of the present invention have excellent properties in the aspects of leaching time, biological release, chemical stability and processing adaptability.